Biogen (BIIB) PT Raised to $435 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $252.73 --0%
Rating Summary:
30 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 11 | New: 14
Rating Summary:
30 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 11 | New: 14
Join SI Premium – FREE
JPMorgan analyst Cory Kasimov raised the price target on Biogen (NASDAQ: BIIB) to $435.00 (from $269.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Biogen (BIIB) Tops Q3 EPS by 60c, Beats on Revenue; Offers FY26 EPS Guidance
- PayPal (PYPL) PT Raised to $46 at Morgan Stanley
- Seagate Technology (STX) PT Lowered to $1,148 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
